drugset / Trial / NCT00348673
A Study in Asymptomatic HIV Infected Patients to Investigate Pharmacodynamics, Pharmacokinetics, Safety and Toleration of UK-453,061
RandomizedSingle-groupDouble-blindTreatment
Summary
A phase 2a study to investigate the effects of 7-day monotherapy of UK-453,061 on viral load response in asymptomatic human immunodeficiency virus (HIV) infected subjects, to assess the dose-response relationship, and to assess the pharmacokinetics (PK), safety and tolerability of UK-453,061 in asymptomatic HIV infected subjects.
Timeline
- Start
- 2006-02
- Primary completion
- 2007-02
- Completion
- 2007-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lersivirine | Small molecule | 10 mg | — |
| Subject | Lersivirine | Small molecule | 30 mg | — |
| Subject | Lersivirine | Small molecule | 100 mg | — |
| Subject | Lersivirine | Small molecule | 500 mg | — |
| Subject | Lersivirine | Small molecule | 750 mg | — |
Indications
No indication recorded.